These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8913385)

  • 41. A first-phase quality assurance program for intravenous admixture aseptic technique.
    Gurwich EL; Hanold L; Schaeffer P
    Hosp Pharm; 1982 Mar; 17(3):119-21. PubMed ID: 10255637
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sterility of intravenous therapy in home care settings.
    Catania PN; Ogbru O
    Home Care Provid; 1999 Feb; 4(1):19-20. PubMed ID: 10222932
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A managed care model for home infusion therapy.
    Cerra FB; Kaplan EL; Schwarzenberg SJ; Soltis R; Twiggs L
    Am J Med Qual; 1995; 10(2):93-9. PubMed ID: 7787505
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Quality assurance in I.V. admixture programs.
    Turco SJ
    Hosp Pharm; 1979 Jun; 14(6):307, 311-3. PubMed ID: 10242204
    [No Abstract]   [Full Text] [Related]  

  • 45. Regulatory framework of pharmaceutical compounding and actual developments of legislation in Europe.
    Minghetti P; Pantano D; Gennari CG; Casiraghi A
    Health Policy; 2014 Sep; 117(3):328-33. PubMed ID: 25110297
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Joint Commission expectations related to USP-NF Chapter 797 on compounding sterile preparations.
    Jt Comm Perspect; 2006 Apr; 26(4):5. PubMed ID: 16786622
    [No Abstract]   [Full Text] [Related]  

  • 47. Taking the risk. Despite meningitis outbreak, some hospitals have little choice but to rely on compounding pharmacies.
    Lee J; Barr P
    Mod Healthc; 2012 Oct; 42(42):6-7, 16, 1. PubMed ID: 23163082
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of two work practice changes on the microbial contamination rates of pharmacy-compounded sterile preparations.
    Trissel LA; Gentempo JA; Saenz LM; Woodard MY; Angeles CH
    Am J Health Syst Pharm; 2007 Apr; 64(8):837-41. PubMed ID: 17420200
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Compounding facilities assessment and planning: A focus on USP <797> and USP <800>.
    Clark JS; Tharp JC; Patel D; Desmarais A
    Am J Health Syst Pharm; 2020 Oct; 77(22):1910-1913. PubMed ID: 32839816
    [No Abstract]   [Full Text] [Related]  

  • 50. Quality assurance for the JCAHO standards.
    Chase PA
    Am J Hosp Pharm; 1991 Jul; 48(7):1550-2. PubMed ID: 1882891
    [No Abstract]   [Full Text] [Related]  

  • 51. Impact of enhanced compounding vigilance: Three perspectives.
    Lucarotti A; Kent S; Strickland J; Desmond JS
    Am J Health Syst Pharm; 2020 Jun; 77(13):1071-1077. PubMed ID: 32382741
    [No Abstract]   [Full Text] [Related]  

  • 52. Compounding practices in Iran.
    Goodarzi N; Niknam S; Akbarzadeh T; Gholami K
    Int J Pharm Compd; 2014; 18(2):112-6. PubMed ID: 24881113
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ASHP technical assistance bulletin on compounding nonsterile products in pharmacies. American Society of Hospital Pharmacists.
    Am J Hosp Pharm; 1994 Jun; 51(11):1441-8. PubMed ID: 7942879
    [No Abstract]   [Full Text] [Related]  

  • 54. Comprehensive intravenous admixture services: logistics and quality assurance in a university affiliated teaching institution.
    Wellman GS; Hale KM; Schneider PJ; Hale KN
    Hosp Pharm; 1984 Sep; 19(9):601-6. PubMed ID: 10267935
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Auditing Safety of Compounding and Reconstituting of Intravenous Medicines on Hospital Wards in Finland.
    Suvikas-Peltonen E; Palmgren J; Häggman V; Celikkayalar E; Manninen R; Airaksinen M
    Int J Pharm Compd; 2017; 21(6):518-529. PubMed ID: 29220341
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design and implementation of a quality-assurance program for pharmaceutical services.
    Horowitz KN; Lamnin M
    Am J Hosp Pharm; 1980 Jan; 37(1):82-4. PubMed ID: 7361777
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Compounding sterile preparations raises informed-consent issues.
    Young D
    Am J Health Syst Pharm; 2003 Jun; 60(12):1209-10. PubMed ID: 12845913
    [No Abstract]   [Full Text] [Related]  

  • 58. Quality Assurance and Quality Control: Being Prepared for U.S. Food and Drug Administration Inspections and Staying in Compliance with United States Pharmacopeia Chapter <797>: Part 1.
    Martin M
    Int J Pharm Compd; 2018; 22(5):401-404. PubMed ID: 30384338
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quality and productivity assessment of clinical pharmacy interventions.
    Baciewicz AM; Cowan RI; Michaels PE; Kyllonen KS
    Hosp Formul; 1994 Nov; 29(11):773, 777-9. PubMed ID: 10138574
    [TBL] [Abstract][Full Text] [Related]  

  • 60. End-preparation assessments and tests for compounded sterile preparations.
    McElhiney LF
    Int J Pharm Compd; 2013; 17(4):307-11. PubMed ID: 24261146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.